University of Groningen

Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients

Tkaczyszyn, Michal; Comin-Colet, Josep; Voors, Adriaan A.; van Veldhuisen, Dirk J.; Enjuanes, Cristina; Moliner, Pedro; Drozd, Marcin; Sierpinski, Radoslaw; Rozentryt, Piotr; Nowak, Jolanta

Published in:
European Journal of Heart Failure

DOI:
[10.1002/ejhf.2253](https://doi.org/10.1002/ejhf.2253)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Tkaczyszyn, M., Comin-Colet, J., Voors, A. A., van Veldhuisen, D. J., Enjuanes, C., Moliner, P., Drozd, M., Sierpinski, R., Rozentryt, P., Nowak, J., Suchocki, T., Banasiak, W., Ponikowski, P., van der Meer, P., & Jankowska, E. A. (2021). Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. *European Journal of Heart Failure*, 23(10), 1677–1686.
<https://doi.org/10.1002/ejhf.2253>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients

Michał Tkaczyszyn^{1,2*}, Josep Comín-Colet^{3,4}, Adriaan A. Voors⁵, Dirk J. van Veldhuisen⁵, Cristina Enjuanes^{3,4}, Pedro Moliner^{3,4}, Marcin Drozd^{1,2}, Radosław Sierpiński⁶, Piotr Rozentryt⁷, Jolanta Nowak⁷, Tomasz Suchocki⁸, Waldemar Banasiak⁹, Piotr Ponikowski^{1,2}, Peter van der Meer⁵, and Ewa A. Jankowska^{1,2}

¹Department of Heart Diseases, Wrocław Medical University, Wrocław, Poland; ²Centre for Heart Diseases, University Hospital, Wrocław, Poland; ³Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; ⁴Community Heart Failure Program, Cardiology Department, University Hospital Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; ⁵Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; ⁶Medical Research Agency, Warsaw, Poland; ⁷Silesian Centre for Heart Disease and Silesian Medical University, Zabrze, Poland; ⁸Biostatistics Group, Department of Genetics, Wrocław University of Environmental and Life Sciences, Wrocław, Poland; and ⁹Cardiology Department, Centre for Heart Diseases, Military Hospital, Wrocław, Poland

Received 27 January 2021; revised 22 April 2021; accepted 24 May 2021

Aims

Abnormal endogenous erythropoietin (EPO) constitutes an important cause of anaemia in chronic diseases. We analysed the relationships between iron deficiency (ID) and the adequacy of endogenous EPO in anaemic heart failure (HF) patients, and the impact of abnormal EPO on 12-month mortality.

Methods and results

We investigated 435 anaemic HF patients (age: 74 ± 10 years; males: 60%; New York Heart Association class I or II: 39%; left ventricular ejection fraction: $43 \pm 17\%$). Patients with EPO higher than expected for a given haemoglobin were considered EPO-resistant whereas those with EPO lower than expected - EPO-deficient. ID was defined as serum ferritin $<100 \mu\text{g/L}$ or $100\text{--}299 \mu\text{g/L}$ with transferrin saturation $<20\%$. EPO-resistant patients (22%) had more advanced HF whereas those with EPO deficiency (57%) were more frequently females and had worse renal function. Lower serum ferritin (indicating depleted body iron stores) was related to higher EPO observed/predicted ratio when adjusted for significant clinical confounders, including C-reactive protein. One year all-cause mortality was 28% in patients with EPO resistance compared to 17% in patients with EPO deficiency and 10% in patients with adequate EPO (log-rank test for the comparison EPO resistance vs. adequate EPO: $P = 0.02$). When adjusted for other prognosticators, there was still a trend towards increased 12-month mortality in patients with higher EPO level.

Conclusion

Anaemic HF patients with endogenous EPO deficiency vs. resistance have different clinical and laboratory characteristics. In such patients, ID contributes to EPO resistance independently of inflammation.

*Corresponding author. Laboratory for Applied Research on Cardiovascular System, Department of Heart Diseases, Wrocław Medical University and Centre for Heart Diseases, University Hospital; ul. Borowska 213, 50-556 Wrocław, Poland. Tel: +48 71 7331112, Email: michal.tkaczyszyn@umed.wroc.pl

Graphical Abstract

The majority of anaemic HF patients have abnormal endogenous erythropoietin (EPO) level, and patients with endogenous EPO deficiency versus resistance have different clinical and laboratory characteristics. In such patients, depleted body iron stores contribute to the resistance to endogenous EPO independently of inflammation.

Keywords

Heart failure • Iron deficiency • Anaemia • Erythropoietin • Mortality

Introduction

Absolute or functional deficiency of endogenous erythropoietin (EPO) constitutes an important cause of anaemia in different chronic diseases.^{1,2} For example, in advanced chronic kidney disease (CKD) many patients either develop an absolute EPO deficiency due to its decreased renal production, or present with resistance to endogenous EPO as the result of a chronic pro-inflammatory state.³ Importantly, in the haematology literature, patients with anaemia due to iron deficiency (ID) have comparable haemoglobin concentration but higher circulating EPO than patients with anaemia of chronic disease, which suggests the contribution of ID to endogenous EPO resistance.⁴ In anaemic heart failure (HF) patients, quantitative and qualitative derangements regarding endogenous EPO contribute to the development and progression of anaemia; however, it is still unclear whether particular pathomechanisms known from other chronic conditions such as CKD are also valid in the HF population.⁵

Hence, in the current study we aimed to investigate: (i) the prevalence of endogenous EPO deficiency and resistance in anaemic HF patients, (ii) the relationships between inflammation, ID and EPO level in these patients, and (iii) the impact of abnormal EPO on 12-month mortality.

Methods

Patients

The baseline study population comprised 1821 patients with stable, chronic HF with a broad range of left ventricular ejection fraction (mean ± standard deviation: 35 ± 15%, median: 32%)⁶ from five cohorts from: (i) Poland (two cohorts, $n = 735$),^{7,8} (ii) Spain (one cohort, $n = 789$),⁹ and (iii) the Netherlands (two cohorts, $n = 297$)^{10,11} as described previously. Detailed inclusion and exclusion criteria for each cohort are available as an online Appendix to the primary paper.⁶ Of the original international pooled cohort including 1821 patients, 587 enrollees (32%) were anaemic (haemoglobin <13.0 g/dL in men and <12.0 g/dL in women, based on World Health Organization definition),¹² which prevalence is comparable to one large systematic review on anaemia in chronic HF.¹³ Here we report on 435 HF patients with anaemia who had endogenous EPO measured at enrolment, which constitute 74% of all anaemic subjects. At the time of the inclusion in the study (during the outpatient visit or at elective hospitalization), none of the patients recruited were treated with erythropoiesis-stimulating agents (ESA) or intravenous iron therapy, and neither had blood transfusions. All study protocols were approved by the local ethics committees, and all patients gave written informed consent. The study was conducted in accordance with the Helsinki Declaration.

Erythropoietin, haematological parameters, iron status, and other laboratory tests

All laboratory tests were measured only at baseline. Laboratory measurements were performed locally at each centre. After centrifuging, some plasma and serum were collected and frozen for further analyses. Endogenous EPO was measured using an immunoassay. Haemoglobin and red cell indices were measured in fresh venous blood. The following iron parameters were measured directly: ferritin ($\mu\text{g/L}$), serum iron ($\mu\text{g/dL}$), total iron binding capacity (TIBC, $\mu\text{g/dL}$), and transferrin (mg/dL). Serum ferritin was measured using an immunoassay. Serum iron and TIBC were assessed using a substrate method. Transferrin saturation (TSAT) was calculated as a ratio of $0.7217 \times$ serum iron and transferrin, multiplied by 100.¹⁴ When transferrin was not available, TSAT was calculated as a ratio of serum iron and TIBC, multiplied by 100. ID was defined based on large randomized controlled trials on ID in HF as serum ferritin $<100 \mu\text{g/L}$ (absolute ID) or serum ferritin $100\text{--}299 \mu\text{g/L}$ in combination with a TSAT $<20\%$ (functional ID).^{15,16} Serum soluble transferrin receptor (sTfR) was measured using immunonephelometry or an enzyme immunoassay. Patients' renal function was assessed using estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease equation.¹⁷ C-reactive protein (CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were measured using conventional methods.

Adequacy of endogenous erythropoietin

The adequacy of endogenous EPO in investigated anaemic HF patients was evaluated using the observed/predicted (O/P) ratio as previously described.⁵ EPO O/P ratio was calculated as follows: $\log_{10}(\text{EPO observed})/\log_{10}(\text{EPO predicted})$. Predicted concentration of EPO was calculated with the following formula: $\log_{10}(\text{EPO}) = 4.640 - [0.274 \times \text{haemoglobin}]$.⁵ Patients with EPO higher than expected for a given haemoglobin (EPO O/P ratio >1.087) were considered EPO-resistant, whereas those with EPO levels lower than expected (EPO O/P ratio <0.916) were classified as EPO-deficient.⁵

Statistical analyses

Most continuous variables had a normal distribution, and were expressed as a mean $\pm$ standard deviation. The inter-group differences were tested using the analysis of variance (ANOVA) with post-hoc Scheffé's tests. NT-proBNP, eGFR, CRP, ferritin, and EPO had a skewed distribution, and were log-transformed (a natural logarithm, ln) before the inclusion in further analyses. These variables were expressed as median with interquartile range (IQR), and the inter-group differences were tested after ln-transformation. Categorized variables were expressed as number and proportion (%), and the inter-group differences were tested using the Chi-square test. Univariable logistic regression analyses were applied to establish the variables associated with the higher prevalence of EPO resistance or EPO deficiency (both vs. adequate EPO). As potential risk factors for the greater prevalence of inadequate EPO, we analysed variables describing the severity and aetiology of HF, comorbidities, iron status, red cell indices, and other laboratory parameters.

Univariable and multivariable linear regression analyses were applied to establish variables associated with EPO O/P ratio. In univariable analyses, as potential correlates of EPO O/P ratio, we included parameters describing the severity and aetiology of HF, comorbidities, iron status,

red cell indices, and other laboratory parameters. During the construction of multivariable models, we included significant ($P < 0.05$) determinants of EPO O/P ratio from univariable analyses.

The associations between analysed variables related to the adequacy of endogenous EPO with 12-month mortality were evaluated using univariable and multivariable Cox proportional hazard regression models. The impact of endogenous EPO level (ln), EPO O/P and abnormal (higher or lower than expected) vs. adequate EPO on 12-month mortality was tested alone (univariable models) and after adjusting for other significant prognosticators from univariable analyses. We also verified whether the impact of endogenous EPO on 12-month mortality may be U-shaped using the natural cubic splines methodology. Additionally, we constructed Kaplan–Meier curves to compare survival in patients with EPO resistance or deficiency vs. adequate EPO. Twelve-month mortality between these three groups of patients was compared using log-rank tests. The length of follow-up of survivors and patients who died later than 12 months after enrolment was censored at 365 days.

A P -value of <0.05 was considered statistically significant. Statistical analyses were performed using the Statistica 13.3 data analysis software system (TIBCO, Inc).

Results

Prevalence and clinical correlates of abnormal endogenous erythropoietin

Baseline clinical characteristics of examined patients with HF are presented in Table 1. Overall, 22% of patients were EPO-resistant, 57% EPO-deficient, and only 21% had an adequate EPO level. Patients with EPO resistance compared with those with adequate EPO were characterized by more severe HF symptoms, lower left ventricular ejection fraction (LVEF), higher NT-proBNP, and slightly higher haemoglobin (Table 1, Figure 1). Patients with EPO deficiency (vs. those with EPO within normal range) were more frequently female and had worse renal function (Table 1, Figure 1). Among 435 analysed anaemic HF patients, 292 subjects were iron-deficient (67%), including 122 with functional and 170 with absolute ID (28% and 39%, respectively). Patients with absolute ID had a median EPO of 25 U/L (IQR $16\text{--}42$), with functional ID 19 U/L ($12\text{--}44$), and subjects without ID 19 U/L ($11\text{--}30$) [P -value for ANOVA $=0.001$ and P -value for post-hoc comparison between absolute ID vs. no ID $=0.001$; the other two post-hoc comparisons (functional vs. absolute ID and no ID vs. functional ID) were not significant]. In the group of investigated patients with HF as much as 77% were receiving angiotensin-converting enzyme inhibitor or angiotensin receptor blocker at enrolment, 86% beta-blocker, 41% aldosterone antagonist, and 91% loop diuretic. EPO level (ln) did not correlate with the use of aforementioned key groups of HF drugs (all $P > 0.2$). EPO O/P ratio was greater in subjects taking aldosterone antagonist ($r = 0.14$, $P = 0.006$) but this observation was not valid for other aforementioned groups of drugs (all $P > 0.6$).

Associations between iron status and abnormal erythropoietin

In multivariable linear regression models, concomitant ID as well as lower serum ferritin were related to higher EPO O/P

Table 1 Baseline characteristics of anaemic heart failure patients according to the adequacy of endogenous erythropoietin (EPO). Clinical and laboratory correlates of EPO resistance and EPO deficiency (univariable logistic regression analyses)

Variable	N	Baseline characteristics and intergroup comparisons			Univariable logistic regression analyses OR (95% CI) χ^2				
		All patients with HF (n = 435)	Patients with EPO within expected range (n = 90) [EPO O/P: 0.916–1.087]	Patients with EPO higher than expected (n = 95) [EPO O/P: 1.087] ^a	Patients with EPO lower than expected (n = 250) [EPO O/P: 0.916] ^a	P-value for ANOVA/ χ^2 test	Unit	Prediction of EPO resistance higher than expected vs. normal EPO	Prediction of EPO deficiency (EPO lower than expected vs. normal EPO)
Age (years)	435	74 ± 10	72 ± 10	73 ± 10	74 ± 10	0.377	Year	–	–
Male sex	435	261 (60%)	62 (69%)	76 (80%)	123 (49%)**	<0.001	Male vs. female	–	0.44 (0.26–0.73) 10.1**
BMI (kg/m ²)	410	27.9 ± 5.6	28.5 ± 6.3	27.4 ± 4.6	27.9 ± 5.6	0.474	kg/m ²	–	–
NYHA class (I–II/III–IV)	435	169/266 (39/61%)	37/53 (41/59%)	24/71 (25/75%)*	108/142 (43/57%)*	0.008	III–IV vs. I–II	2.07 (1.10–3.87) 5.17*	–
HF aetiology, ischaemic	435	225 (52%)	50 (56%)	61 (64%)	114 (46%)	0.006	Ischaemic vs. non-ischaemic	–	–
LVEF (%)	435	43 ± 17	43 ± 16	37 ± 17**	45 ± 17	<0.001	%	0.98 (0.96–0.99) 6.87**	–
NT-proBNP (pg/mL)	429	2274 (948–5210)	2223 (1118–4874)	3670 (1375–7662)*	1959 (818–4599)	0.002	ln pg/mL	1.31 (1.03–1.66) 5.11*	–
eGFR (mL/min/1.73 m ²)	435	73 (47–119)	84 (60–132)	75 (47–121)	68 (43–113)*	0.047	ln mL/min/1.73 m ²	–	0.61 (0.41–0.90) 6.22*
CRP (mg/L)	381	1.3 (0.4–3.8)	1.0 (0.4–3.4)	1.4 (0.4–4.5)	1.3 (0.4–3.8)	0.188	ln mg/L	–	–
Comorbidities									
Arterial hypertension, yes	432	318 (74%)	62 (70%)	65 (68%)	191 (77%)	0.173	Yes vs. no	–	–
Diabetes, yes	426	222 (52%)	44 (50%)	47 (50%)	131 (54%)	0.753	Yes vs. no	–	–
Atrial fibrillation, yes	410	106 (26%)	25 (30%)	27 (30%)	54 (23%)	0.227	Yes vs. no	–	–
Iron status									
Iron deficiency, yes	435	292 (67%)	64 (71%)	69 (73%)	159 (64%)	0.186	Yes vs. no	–	–
Iron (µg/dL)	435	52 ± 33	51 ± 28	52 ± 26	53 ± 36	0.946	µg/dL	–	–
Ferritin (µg/L)	435	139 (61–261)	119 (51–233)	106 (56–252)	151 (72–289)	0.111	ln µg/L	–	–
TSAT (%)	435	16 ± 10	15 ± 8	16 ± 9	16 ± 11	0.539	%	–	–
sTfR (mg/L)	270	1.93 ± 1.01	1.93 ± 0.84	2.33 ± 1.15*	1.83 ± 1.01	0.013	mg/L	–	–
Red cell indices and EPO									
Haemoglobin (g/dL)	435	11.2 ± 1.2	11.4 ± 1.0	12.0 ± 0.8***	10.7 ± 1.1***	<0.001	g/dL	1.98 (1.40–2.79) 15.3***	0.54 (0.41–0.69) 22.4***
MCV (fL)	378	90 ± 7	91 ± 7	89 ± 7	89 ± 7	0.259	fL	–	–
MCH (pg)	365	28 ± 3	29 ± 3	29 ± 3	28 ± 3	0.632	pg	–	–
MCHC (g/dL)	365	32 ± 1	32 ± 1	32 ± 2	32 ± 1	0.230	g/dL	–	–
EPO (U/L)	435	21.0 (12.0–37.0)	28.6 (19.0–47.7)	50 (31–81)***	14.0 (9.0–22.0)***	<0.001	U/L	–	–

Data are presented as mean ± standard deviation, median (with lower and upper quartile), or n (%), as appropriate.

Iron deficiency was defined as ferritin <100 µg/L or 100–299 µg/L with TSAT <20%.

BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; EPO, erythropoietin; HF, heart failure; ln, natural logarithm; LVEF, left ventricular ejection fraction; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular volume; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; O/P, observed/predicted ratio; OR, odds ratio; sTfR, soluble transferrin receptor; TSAT, transferrin saturation.

^aP-values are presented for the comparison with the group 'EPO within expected range' (post-hoc).

**P < 0.05.

***P < 0.01.

****P < 0.001.

ratio when adjusted for relevant clinical and laboratory confounders, including CRP (Table 2). The relationship between serum ferritin (ln) and EPO O/P ratio (linear regression slope) is shown in Figure 2. In a multivariable model comprising sTfR as an indicator of iron status, this parameter did not reach pre-defined level of statistical significance as an independent correlate of endogenous EPO O/P ratio ($\beta = 0.028$, $P = 0.076$) (Table 2).

Adequacy of endogenous erythropoietin and 12-month all-cause mortality

Follow-up was available for 283 patients and its median duration was 501 days (range: 1–3775). Median time to death (in 107 patients with reported death) was 468 days (range: 1–3314). Only 26 survivors had the duration of follow-up <365 days (one patient: 31 days; remaining 25 enrollees: 112–364 days). There was no difference regarding 12-month all-cause mortality in EPO-deficient patients (17%) vs. adequate EPO group (10%; log-rank test: $P = 0.23$), whereas EPO-resistant patients had higher mortality (28%) as compared with adequate EPO (log-rank: $P = 0.02$), and there was also a trend towards greater mortality in patients with EPO resistance vs. EPO deficiency (log-rank: $P = 0.06$) (Figure 3). When adjusted for relevant prognosticators from univariable analyses (i.e. HF severity and neurohormonal activation), there was still a trend towards higher 12-month mortality in patients with higher EPO (Table 3). To verify the potential U-shaped relationship between endogenous EPO and survival, we applied the natural cubic splines with five knots, but it did not influence significantly the 12-month all-cause mortality in investigated patients with HF and anaemia (EPO included as a cubic spline in the multivariable model: $P = 0.28$) (Figure 4).

Discussion

There are two major findings arising from our observational study. First, clinical and laboratory characteristics were different between patients with endogenous EPO deficiency and resistance, compared to those with adequate EPO levels. Second, ID contributed to endogenous EPO resistance but not EPO deficiency.

Heart failure and renal dysfunction frequently coexist and the pathophysiological concept of a 'cardio-renal anaemia syndrome' has been widely discussed in the literature.^{18,19} Importantly, although HF and CKD share some pathophysiological phenomena related to erythropoiesis,^{20,21} the mechanisms leading to anaemia in these two conditions are not entirely analogous.²⁰ Abnormal endogenous EPO has been previously shown to contribute to anaemia in HF.²² In the study of van der Meer *et al.*⁵ out of 74 chronic HF patients with concomitant anaemia, 29 were EPO-deficient and 22 EPO-resistant, and EPO O/P ratio correlated with CRP ($r = 0.3$, $P = 0.02$). Indeed, chronic pro-inflammatory state with excess of circulating cytokines, occurring in various chronic disorders, impedes erythropoiesis within the bone marrow which is orchestrated by endogenous EPO.²³ Although chronic low-grade inflammation (with the retention of iron in

mononuclear phagocyte system as one of its pathophysiological features) has been considered the key mechanism of EPO resistance in HF patients, data from haematological literature led us to hypothesize that also depleted iron stores may play a role in hampering pro-erythropoietic effects of endogenous EPO. For example, Theurl *et al.*⁴ measured endogenous EPO levels in patients with anaemia of different aetiology, and demonstrated that subjects with iron-deficient anaemia have comparable haemoglobin but higher EPO, compared to the group with anaemia of chronic disease (recently 'anaemia of inflammation'). In the course of HF, one more mechanism may be responsible for a blunted response of the bone marrow to increasing endogenous EPO. Namely, the adaptive increase in the production of erythrocytes (as a response to progressive anaemia) is precisely orchestrated by the group of transcription factors called hypoxia-inducible factors (HIFs), which exert their pro-erythropoietic effects in a multidimensional way.²⁴ It needs to be acknowledged that HIFs not only stimulate renal (and liver) production of EPO, but also affect the microenvironment of the bone marrow, preparing it for increased proliferation of red blood cells.²⁴ There is experimental evidence from animal HF models that HIF signalling is abnormal in the course of cardiac volume overload.²⁵ One may ask the question if in the course of HF the bone marrow response to HIFs is as effective as that of the kidneys, irrespective of overlapping immune-driven mechanisms that were described above. The complex interplay between HIF signalling, chronic low-grade inflammation, dysregulated iron status, and anaemia in the course of HF requires further mechanistic research.

In our study we have shown that in anaemic HF patients, concomitant ID is related to higher EPO O/P ratio when adjusted for patient sex, HF severity, neurohormonal activation, renal function, and inflammation. Importantly, this relationship was driven predominantly by the depletion of iron stores, as reflected by lower serum ferritin. Analogously, circulating EPO level was comparably lower in subjects with functional ID and without ID (median 19 U/L for both groups), compared with subjects with absolute ID who had significantly greater EPO (median 25 U/L). This observation is another argument supporting the hypothesis that in anaemic HF patients without severe inflammation (such as for example in end-stage renal disease with uraemia) an absolute decrease in body iron (predominantly due to impaired intestinal iron absorption?) inhibits the actions of disproportionately elevated EPO to a greater extent than the immune-driven retention of iron in the mononuclear phagocyte system. The latter retention is the key element of anaemia of inflammation, in the course of which body iron stores do not have to be reduced.²⁶ Median CRP for our study group (1.3 mg/L) confirms that inflammatory processes were not severe in examined patients, comparing for example with the population of haemodialysed patients with end-stage renal disease. Our results indicate that mechanisms of EPO resistance related to absolute ID compared with inflammation-related functional ID may not be the same. Importantly, we have shown that ID can contribute to endogenous EPO resistance in anaemic HF patients in a broad spectrum of LVEF. Indeed, although ID complicating HF has been initially investigated (and treated) in subjects with lower values of LVEF,^{15,16} now we have data that it is also common in HF with mid-range and

Figure 1 Prevalence and clinical correlates of abnormal endogenous erythropoietin (EPO) in anaemic heart failure (HF) patients. LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; O/P, observed/predicted.

preserved LVEF, and detrimental clinical effects of ID (decreased exercise capacity and worse outcomes) are evident across all LVEF categories.²⁷

Importantly, our study group is also unique because all patients had concomitant anaemia. It needs to be acknowledged that ‘universal’ HF prognosticators – i.e. identified for all HF patients irrespective of the anaemia status – should not be simply extrapolated to anaemic subjects, who themselves have worse prognosis.^{13,28} For example, in our cohort, NT-proBNP was not an independent predictor of increased 12-month mortality in the multivariable model. This may be due to the fact that anaemia itself affects circulating natriuretic peptides by increasing plasma volume, which effect is independent of current degree of HF-related congestion.^{29,30} On the other hand, in the sub-analysis of the RED-HF clinical trial (see below) the prognostic value of

Table 2 Associations between endogenous erythropoietin observed/predicted ratio and clinical variables, comorbidities, iron status, and red cell indices in anaemic heart failure patients

Correlates of EPO O/P ratio (units)	Univariable models	Multivariable model with ID (corrected $R^2 = 13\%$, $P < 0.001$)	Multivariable model with ferritin (corrected $R^2 = 14\%$, $P < 0.001$)	Multivariable model with sTfR (corrected $R^2 = 13\%$, $P < 0.001$)
Age (years)	−0.002 [#]			
Sex (male vs. female)	0.156***	0.115***	0.118***	0.071*
BMI (kg/m ²)	0.002			
NYHA class (III–IV vs. I–II)	0.074**	0.050 [#]	0.050 [#]	0.021
HF aetiology (ischaemic vs. non-ischaemic)	0.098***	0.040	0.041	0.031
LVEF (%)	−0.004***	−0.001	−0.001	0.000
NT-proBNP (ln pg/mL)	0.040***	0.027*	0.029**	0.055***
eGFR (ln mL/min/1.73 m ²)	0.043*	0.068**	0.070**	0.085**
CRP (ln mg/L)	0.032*	0.009	0.015	−0.053*
Comorbidities				
Arterial hypertension (yes vs. no)	−0.060 [#]			
Diabetes (yes vs. no)	−0.007			
Atrial fibrillation (yes vs. no)	0.047			
Iron status				
Iron deficiency (yes vs. no)	0.069*	0.059*		
Iron (μg/dL)	−0.000			
Ferritin (ln μg/L)	−0.030**		−0.038**	
TSAT (%)	−0.002			
sTfR (mg/L)	0.052**			0.028 [#]
Red cell indices				
MCV (fL)	0.002			
MCH (pg)	0.006			
MCHC (g/dL)	0.012			

Data are presented as regression coefficients β (both in univariable and multivariable models) between erythropoietin observed/predicted ratio (EPO O/P, dependent variable in the multivariable model) and other variable/variables.

BMI, body mass index; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HF, heart failure; ln, natural logarithm; ID, iron deficiency; LVEF, left ventricular ejection fraction; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular volume; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; sTfR, soluble transferrin receptor; TSAT, transferrin saturation.

[#] $P < 0.1$ (trend).

* $P < 0.05$.

** $P < 0.01$.

*** $P < 0.001$.

Figure 2 Relationship between endogenous erythropoietin observed/predicted (EPO O/P) ratio and a natural logarithm of serum ferritin in patients with heart failure and anaemia [linear regression slope (solid line) with 95% confidence interval range (dashed lines)].

Figure 3 Kaplan–Meier survival curves for 12-month survival free of all-cause death for the three different groups of anaemic heart failure patients according to the adequacy of endogenous erythropoietin (EPO) level. Censored observations are marked with a cross and uncensored with a circle. *P*-values for the two-group comparisons are presented for the log-rank test, and for the three-group comparison there are presented the results for the Chi-square test.

NT-proBNP outperformed other analysed biomarkers for predicting adverse cardiac outcomes in chronic systolic HF patients with mild or moderate anaemia.³¹ Nevertheless, the results of our study underline the differences between anaemic subjects and the general population of HF patients.

We have also demonstrated that advanced age, more severe HF symptoms and worse renal function were independent predictors of increased 12-month mortality, and there was a trend towards

higher mortality in subjects with higher endogenous EPO. The latter trend for worse prognosis in subjects with elevated EPO is consistent with previous findings demonstrating significant clinical burden related to EPO resistance in anaemic HF patients.⁵ One may hypothesize that endogenous EPO resistance is not a separate pathology but only a bystander in the progression of HF, as EPO O/P ratio was indeed higher in patients with more advanced cardiac disease. However, multivariable prognostic models included

Table 3 Prognosticators of 12-month all-cause mortality in patients with heart failure and anaemia (Cox proportional hazard regression models)

Prognosticator (unit)	Univariable models				Multivariable model <i>n</i> = 239, χ^2 = 45.4, <i>P</i> < 0.001			
	HR	95% CI	χ^2	P-value	HR	95% CI	χ^2	P-value
Age (years)	1.05	1.02–1.09	9.34	0.002	1.07	1.02–1.11	8.88	0.003
Sex (male vs. female)	1.33	0.73–2.39	0.87	0.351				
BMI (kg/m ²)	0.96	0.91–1.02	1.84	0.175				
NYHA class (III–IV vs. I–II)	3.28	1.40–7.69	7.47	0.006	3.31	1.14–9.60	4.85	0.027
HF aetiology (ischaemic vs. non-ischaemic)	1.73	0.97–3.10	3.40	0.065				
LVEF (%)	0.99	0.97–1.00	2.11	0.146				
NT-proBNP (ln pg/mL)	1.64	1.30–2.08	17.3	<0.001	1.12	0.81–1.54	0.47	0.495
eGFR (ln mL/min/1.73 m ²)	0.31	0.19–0.50	22.2	<0.001	0.40	0.21–0.77	7.63	0.006
CRP (ln mg/L)	1.40	1.08–1.81	6.62	0.010	1.05	0.80–1.38	0.14	0.707
Comorbidities								
Arterial hypertension (yes vs. no)	0.86	0.48–1.53	0.27	0.606				
Diabetes (yes vs. no)	1.12	0.64–1.95	0.15	0.700				
Atrial fibrillation (yes vs. no)	0.72	0.35–1.49	0.80	0.372				
Iron status								
Iron deficiency (yes vs. no)	0.86	0.49–1.53	0.25	0.616				
Iron (µg/dL)	0.99	0.98–1.00	1.57	0.210				
Ferritin (ln µg/L)	1.37	1.02–1.83	4.50	0.034	1.32	0.95–1.84	2.74	0.098
TSAT (%)	0.97	0.94–1.01	2.48	0.115				
sTfR (mg/L)	0.99	0.72–1.37	0.01	0.967				
Red cell indices and EPO adequacy								
Haemoglobin (g/dL)	0.80	0.64–1.01	3.66	0.056				
MCV (fL)	1.01	0.97–1.06	0.21	0.648				
MCH (pg)	0.99	0.88–1.11	0.05	0.832				
MCHC (g/dL)	0.92	0.75–1.13	0.66	0.417				
EPO (ln U/L)	1.60	1.16–2.19	8.45	0.004	1.46	0.97–2.21	3.24	0.072
EPO O/P (ratio)	2.16	0.84–5.56	2.53	0.112				
EPO higher than expected vs. normal	2.95	1.18–7.38	5.33	0.021				
EPO lower than expected vs. normal	1.69	0.70–4.11	1.35	0.245				

BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; EPO, erythropoietin; HF, heart failure; HR, hazard ratio; ln, natural logarithm; LVEF, left ventricular ejection fraction; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular volume; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; O/P, observed/predicted ratio; sTfR, soluble transferrin receptor; TSAT, transferrin saturation.

well-established HF prognosticators and the trend for the EPO was still present, in contrast to e.g. NT-proBNP which was mentioned above. Our study positions disproportionally elevated EPO as one of the elements of the pathophysiology of anaemia in HF, and further observational and interventional studies are needed to address the question whether endogenous EPO could be normalized in this particular patient group. In nephrology, the phenomenon of resistance to ESA in some patients with CKD is widely known, and addressing this clinical issue still remains challenging.³² In such patients depleted iron stores due to e.g. poor nutrition or blood losses are a well recognized cause of ESA hyporesponsiveness (independent of inflammation), and intravenous iron is administered in such patients for the 'conditioning' of ESA therapy.³³ In the previously mentioned randomized, double-blind

RED-HF trial investigating the effects of ESA on morbidity and mortality in patients with systolic HF (the therapy was not effective), the median serum ferritin was 102 µg/L, suggesting that almost half of enrollees had absolute ID at the inclusion.^{34,35} One may hypothesize that depleted iron may trigger the resistance to exogenous ESA in HF analogously to CKD. On the other hand, there is a sub-analysis of this trial demonstrating that baseline iron parameters were not related to the hyporesponsiveness to darbepoetin alfa.³⁶ Indisputably the pathophysiology of abnormal EPO responses in anaemic HF patients requires further research.

Study limitations

This study has certain limitations that should be emphasized. Firstly, of 587 anaemic patients from the original pooled cohort only 74%

Figure 4 Endogenous erythropoietin (EPO, In U/L) and a relative hazard of all-cause death using cubic splines during the 12-month follow-up in patients with heart failure and anaemia.

had measured EPO and were included in aforementioned analyses. Second, follow-up was available for 283 patients and therefore 1-year survival analyses are limited to this number of subjects. Moreover, we do not have precise data on patients' treatment (including intravenous iron, blood transfusions or ESA) before the inclusion in the study (months preceding enrolment) as well as during the follow-up period. Another limitation is that laboratory tests analysed in this study were performed only at baseline and there is no follow-up available with regard to either iron status or the effectiveness of erythropoiesis in examined subjects. Finally, we analysed CRP as the only biomarker of inflammation and it would be worth investigating this aspect more comprehensively by including a wider portfolio of pro-inflammatory cytokines and their receptors.³⁷

Conclusions

The majority of anaemic HF patients have abnormal EPO level, and patients with endogenous EPO deficiency vs. resistance have different clinical and laboratory characteristics. In this patient cohort, depleted iron stores contribute to the resistance to endogenous EPO independently of inflammation. Although we have demonstrated the trend towards increased 12-month mortality in subjects with elevated EPO, the prognostic significance of endogenous EPO resistance in anaemic HF patients requires further research.

Funding

This research was financially supported by the National Science Centre (Poland) grant number 2014/13/B/NZ5/03146.

Conflict of interest: Wroclaw Medical University received an unrestricted grant from Vifor Pharma. M.T. reports personal

fees from V-Wave Ltd, Impulse Dynamics, Eidos Therapeutics, Cytokinetics, outside the submitted work. J.C.-C. reports fees for speaking for Vifor Pharma, unrestricted grant from Vifor Pharma (research) and fees as member of the steering committee of the FAIR-HF and CONFIRM-HF studies, outside the submitted work. A.A.V. and/or his institution received consultancy fees and/or research grants from: Amgen AstraZeneca, Bayer AG, Boehringer Ingelheim, BMS, Cytokinetics, Myokardia, Merck, Novo Nordisk, Novartis, Roche Diagnostics. D.J.v.V. reports a research grant to UMCG Cardiology from Vifor Pharma, during the conduct of the study. P.P. reports grants, personal fees and other from Vifor, during the conduct of the study; personal fees and other from Amgen, Bayer, Novartis, Abbott Vascular, Boehringer Ingelheim, Pfizer, Servier, Astra Zeneca, Cibiem, BMS, Vifor Pharma Ltd., Impulse Dynamics, personal fees from Berlin Chemie, other from Cardiac Dimensions, outside the submitted work. P.v.d.M. reports grants and personal fees from Vifor Pharma, personal fees from Novartis, grants from Ionis, grants and personal fees from AstraZeneca, grants from Pfizer, personal fees from Pharmacosmos, during the conduct of the study. E.A.J. reports grants and personal fees from Vifor Pharma, personal fees from Bayer, Novartis, Abbott, Boehringer Ingelheim, Pfizer, Servier, AstraZeneca, Berlin Chemie, Cardiac Dimensions, Takeda, Gedeon Richter, outside the submitted work. The other authors report no conflict of interest.

References

- Boyd HK, Lappin TR. Erythropoietin deficiency in the anaemia of chronic disorders. *Eur J Haematol* 1991;**46**:198–201.
- Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. *Nephrol Dial Transplant* 2002;**17**(Suppl 11):39–43.
- van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. *Nat Clin Pract Nephrol* 2008;**4**:47–57.
- Theurl I, Mattle V, Seifert M, Mariani M, Marth C, Weiss G. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. *Blood* 2006;**107**:4142–4148.
- van der Meer P, Lok DJ, Januzzi JL, de la Porte PW, Lipsic E, van Wijngaarden J, Voors AA, van Gilst WH, van Veldhuisen DJ. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. *Eur Heart J* 2008;**29**:1510–1515.
- Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. *Am Heart J* 2013;**165**:575–582.e3.
- Jankowska EA, Rosentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. *Eur Heart J* 2010;**31**:1872–1880.
- Jankowska EA, Rosentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, von Haehling S, Doehner W, Banasiak W, Polonski L, Filippatos G, Anker SD, Ponikowski P. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. *J Card Fail* 2011;**17**:899–906.
- Comin-Colet J, Enjuanes C, González G, Torrens A, Cladellas M, Meroño O, Ribas N, Ruiz S, Gómez M, Verdú JM, Bruguera J. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. *Eur J Heart Fail* 2013;**15**:1164–1172.
- Bruggink-André de la Porte PW, Lok DJ, van Wijngaarden J, Cornel JH, Pruijsers-Lamers D, van Veldhuisen DJ, Hoes AW. Heart failure programmes in countries with a primary care-based health care system. Are additional trials necessary? Design of the DEAL-HF study. *Eur J Heart Fail* 2005;**7**:910–920.
- Willemssen S, Hartog JW, Hummel YM, Posma JL, van Wijk LM, van Veldhuisen DJ, Voors AA. Effects of alagebrium, an advanced glycation end-product breaker,

- in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. *Eur J Heart Fail* 2010;**12**:294–300.
12. WHO Scientific Group on Nutritional Anaemias & World Health Organization. Nutritional anaemias. Report of a WHO scientific group. *World Health Organ Tech Rep Ser* 1968;**405**:5–37.
 13. Groeneweld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients: a systematic review and meta-analysis. *J Am Coll Cardiol* 2008;**52**:818–827.
 14. Beilby J, Olynyk J, Ching S, Prins A, Swanson N, Reed W, Harley H, Garcia-Webb P. Transferrin index: an alternative method for calculating the iron saturation of transferrin. *Clin Chem* 1992;**38**:2078–2081.
 15. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med* 2009;**361**:2436–2448.
 16. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J* 2015;**36**:657–668.
 17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;**130**:461–470.
 18. Macdougall IC, Canaud B, de Francisco AL, Filippatos G, Ponikowski P, Silverberg D, van Veldhuisen DJ, Anker SD. Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. *Eur J Heart Fail* 2012;**14**:882–886.
 19. Scrutinio D, Passantino A, Santoro D, Catanzaro R. The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival. *Eur J Heart Fail* 2011;**13**:61–67.
 20. Silverberg DS, Wexler D, Blum B, Iaina A. Anemia in chronic kidney disease and congestive heart failure. *Blood Purif* 2003;**21**:124–130.
 21. Silverberg DS, Wexler D, Iaina A. The role of anemia in congestive heart failure and chronic kidney insufficiency: the cardio renal anemia syndrome. *Perspect Biol Med* 2004;**47**:575–589.
 22. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. *Nat Rev Cardiol* 2011;**8**:485–493.
 23. Okonko DO, Anker SD. Anemia in chronic heart failure: pathogenetic mechanisms. *J Card Fail* 2004;**10**(1 Suppl):S5–S9.
 24. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. *Blood Rev* 2013;**27**:41–53.
 25. Lee JW, Ko J, Ju C, Eltzschig HK. Hypoxia signaling in human diseases and therapeutic targets. *Exp Mol Med* 2019;**51**:1–13.
 26. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. *Blood* 2019;**133**:40–50.
 27. Martens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. *Acta Cardiol* 2018;**73**:115–123.
 28. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. *Eur Heart J* 2006;**27**:65–75.
 29. Willis MS, Lee ES, Grenache DG. Effect of anemia on plasma concentrations of NT-proBNP. *Clin Chim Acta* 2005;**358**:175–181.
 30. Hogenhuis J, Voors AA, Jaarsma T, Hoes AV, Hillege HL, Kragten JA, van Veldhuisen DJ. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. *Eur J Heart Fail* 2007;**9**:787–794.
 31. Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP, Desai AS, Solomon SD, Pfeffer MA, Cheng S, Gullestad L, Aukrust P, Ueland T, Swedberg K, Young JB, Kattan MW, Sattar N, McMurray JJV. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. *Eur J Heart Fail* 2018;**20**:268–277.
 32. Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. *Adv Chronic Kidney Dis* 2009;**16**:94–100.
 33. Santos EJF, Dias RSC, Lima JFB, Salgado Filho N, Miranda Dos Santos A. Erythropoietin resistance in patients with chronic kidney disease: current perspectives. *Int J Nephrol Renovasc Dis* 2020;**13**:231–237.
 34. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees and Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. *N Engl J Med* 2013;**368**:1210–1219.
 35. McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). *Eur J Heart Fail* 2013;**15**:334–341.
 36. van der Meer P, Grote Beverborg N, Pfeffer MA, Olson K, Anand IS, Westenbrink BD, McMurray JJV, Swedberg K, Young JB, Solomon SD, van Veldhuisen DJ. Hyporesponsiveness to darbepoetin alfa in patients with heart failure and anemia in the RED-HF study (Reduction of Events by Darbepoetin alfa in Heart Failure): clinical and prognostic associations. *Circ Heart Fail* 2018;**11**:e004431.
 37. Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart failure. *Heart Fail Rev* 2010;**15**:331–341.